CELEX: 62008TB0149
Language: en
Date: 2010-09-13 00:00:00
Title: Case T-149/08: Order of the General Court of 13 September 2010 — Abbott Laboratories v OHIM — aRigen (Sorvir) (Community trade mark — Opposition proceedings — Application for Community word mark Sorvir — Earlier Community word mark NORVIR — Relative ground for refusal — Article 8(1)(b) of Regulation (EC) No 40/94 (now Article 8(1)(b) of Regulation (EC) No 207/2009))

6.11.2010   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 301/26
            
         Order of the General Court of 13 September 2010 — Abbott Laboratories v OHIM — aRigen (Sorvir)
   (Case T-149/08) (1)
   
   (Community trade mark - Opposition proceedings - Application for Community word mark Sorvir - Earlier Community word mark NORVIR - Relative ground for refusal - Article 8(1)(b) of Regulation (EC) No 40/94 (now Article 8(1)(b) of Regulation (EC) No 207/2009))
   2010/C 301/43
   Language of the case: English
   
      Parties
   
   
      Applicant: Abbott Laboratories (Abbott Park, Illinois, United States) (represented by: S. Schäffler, lawyer)
   
      Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: J. Crespo Carrillo and A. Folliard-Monguiral, Agents)
   
      Other party to the proceedings before the Board of Appeal of OHIM: aRigen, Inc. (Tokyo, Japan)
   
      Re:
   
   Action brought against the decision of the Second Board of Appeal of OHIM of 6 February 2008 (Case R 809/2007-2) relating to opposition proceedings between Abbott Laboratories and aRigen, Inc.
   
      Operative part of the order
   
   The General Court:
   
               1.
            
            
               Annuls the decision of the Second Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM) of 6 February 2008 (Case R 809/2007-2);
            
         
               2.
            
            
               Orders OHIM to bear its own costs and to pay those of Abbott Laboratories.
            
         
      (1)  OJ C 142, 7.6.2008.